Retina

Advanz Pharma and Alvotech announced AVT06, a biosimilar to Eylea, was approved for neovascular age-related macular degeneration

Included is the supplemental Biologics License Application (sBLA) for EYLEA HD seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week dosing across approved indications.

Research reveals how neighborhood social factors impact patients with tractional retinal detachments, highlighting the need for improved access to care and support.

Reliable visualization tools, especially those indicated for ocular use, are crucial for success.

The province's public health insurance scheme, Régie de l’assurance maladie du Québec (RAMQ), covers faricimab for three indications

Best disease, or vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by mutations in the BEST1 gene, leading to progressive vision loss and, in some cases, blindness.

jCyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

The two aim to develop a potential first-in-class melanocortin receptor-targeted treatment for patients with retinal diseases.

RAMQ is a public organization introduced in 1970, following the adoption of the universal health care system in Canada.

A complex case of uveitis linked to syphilis highlights the need for thorough history-taking and multidisciplinary management in diagnosis and treatment.

Salvation of ocular tissues and visual acuity are dependent on early diagnosis, investigators emphasised

Patients weigh in on the value of provider communication.

Advanced imaging and awareness of systemic risk factors are essential.

Highlights from the 2025 Heidelberg Engineering International SPECTRALIS Symposium—And Beyond

New financing will support the company's lead retinitis pigmentosa programme, among other projects

This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated in subjects with non-proliferative diabetic retinopathy

The agreement is for a planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR).